Biotoxtech Co., Ltd. announced that it has received KRW 12 billion in funding from KB Securities Co.,Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd.
July 07, 2024
Share
On July 8, 2024, Biotoxtech Co., Ltd. closed the transaction.
Biotoxtech Co., Ltd. is a Korea-based company engaged in the research of non-clinical evaluation business. The Company provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
Biotoxtech Co., Ltd. announced that it has received KRW 12 billion in funding from KB Securities Co.,Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd.
BIOTOXTECH CO., LTD. 
